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The majority of currently available successful vaccines induce host responses against antigens that are
highly conserved in the targeted pathogens. The diphtheria, tetanus, and pertussis vaccines confer protec-
tion by inducing neutralizing antibodies to the conserved bacterial toxins that are the major virulence factors.
The Hemophilus influenzae B vaccine induces responses to conserved epitopes in the sugar structure of the
bacterial capsular polysaccharide. However, the efficacy of more recently developed vaccines is limited by
antigen variation, which also presents a challenge for future vaccine development. This review will explore
bacterial genome variability and its impact on vaccine development.Introduction
It is no coincidence that the first vaccines developed were
against pathogens with little variability. In fact, the concept of
immunological memory on which vaccination is based was de-
rived from the observation that survival of infection resulted in
lifelong immunity to further episodes of the same disease. Hence
vaccines against stable diseases such as smallpox, measles,
and rubella were very effective in conferring protection. Vaccines
against bacterial pathogenswhose virulencedepends ona single
toxin have also been very effective. While the genomes of the
bacteria causing diphtheria, tetanus, and pertussis (Preston
et al., 2004) may in fact vary considerably, in each of these dis-
eases the major virulence factor is a single toxin. Neutralization
of these toxins by specific antibodies essentially prevents dis-
ease. Corynebacterium diphtheriae is a good example of this.
The diphtheria toxin is carried on a prophage (Pappenheimer,
1977). In the absence of the prophage in the genome, the bacte-
ria are totally harmless. Hence immunization with a detoxified
form of the toxin that is capable of inducing neutralizing anti-
bodies to the active toxin confers effective protection against
disease. The common theme among these often-lethal patho-
gens is that while host survival results in immunity, they are highly
infectious and can be maintained in the population because of
the renewal of nonimmune cohorts of new births.
Later, vaccines became more difficult to develop. The polio
vaccine required three strains of virus to give universal coverage,
but at least these three strains are relatively stable (De Jesus,
2007). Influenza virus is highly variable between one year and
the next, but its infection period is so short that yearly vaccina-
tion with the appropriate strains is effective (Carrat and Flahault,
2007). However, its capacity to reassort its genome with other
strains during coinfection in animal hosts results in the genera-
tion of virulent pandemic strains to which we have no prior im-
mune priming (Hilleman, 2002). Finally, viruses such as HIV
vary even within a single host during a single infection and
have thus resisted all attempts to date to develop a vaccine
(Korber et al., 2001).
Variation in viruses with RNA genomes generally depends on
inaccurate replication due to the lack of proof reading during rep-
lication or in addition, as in the case of influenza, to genome408 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.reassortment and is usually driven by immune pressure and
selection. Variation in bacteria on the other hand reflects a variety
of mechanisms and selection pressures for developing diversity.
This review will concentrate on bacterial antigenic variation and
the resulting difficulties of developing vaccines capable of con-
ferring broad protection.
Capsular Polysaccharide Antigens
Many pathogens are encapsulated bacteria. The capsule is
formed from complex polysaccharides that vary between spe-
cies and even between strains of the same pathogen. While
capsules often help to evade innate immunity, in several cases,
antibodies that recognize the capsular polysaccharide (CPS)
can activate complement deposition and lead to cell killing either
by direct bacterial lysis or by complement dependent opsono-
phagocytic killing of the pathogen (Sood and Fattom, 1998).
Hence, the CPS can be an effective antigen to induce protective
immunity particularly for pathogens that invade the host to cause
septicemia and meningitis. Since polysaccharides are generally
poor antigens that do not induce a T cell response, they are
poorly immunogenic in infants that are the major targets for the
disease. To overcome this, CPS antigens are usually conjugated
to a protein carrier capable of inducing a robust T cell response
resulting in immunogenicity in infants and induction of long-term
memory (Mond and Kokai-Kun, 2008).
Examples of successful vaccines using this strategy are those
against Streptococcus pneumoniae (pneumococcus), Haemo-
philus influenzae, and some serogroups ofNeisseria meningitidis
(meningococcus). Unfortunately, these pathogens have highly
variable capsular serotypes, and there is rarely crossprotection
between serotypes. Pneumococcus, for example, has over
ninety serotypes with little crossprotection (Lipsitch and O’Ha-
gan, 2007). On the other hand, the population structure of pneu-
mococcal strains is fairly stable, and the majority of invasive
disease is caused by a few serotypes. This has led to the devel-
opment of a 23-valent pneumococcal CPS vaccine that confers
limited protection in adults and to a 7-valent conjugate vaccine
that is very effective in both adults and infants (Galiza and Heath,
2007). The seven serotypes included in this latter vaccine ac-
count for about 80% of invasive disease in the US and Europe
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conjugates are currently in development in order to increase
strain coverage. A partly expected result of the widespread
use of the 7-valent pneumococcus vaccine has, however,
been that serotypes not included in the vaccine are beginning
to replace those that are included and disease from these non-
included strains is on the increase (Toltzis and Jacobs, 2005).
Having said that, the value to public health of conjugate vac-
cines, such as theH. influenzaB vaccine, cannot be understated.
A similar situation exists for N. meningitidis. There are five
serotypes (A, B, C, Y, and W135) causing the majority of disease
in the world (Stephens et al., 2007). For four of these, effective
vaccines have been developed or are in development. Serotype
B, which is responsible for up to 50% of disease in Europe and
the USA, cannot, however, be defeated by the same strategy,
since its CPS is composed of polysialic acid, a polysaccharide
found also in human tissues. Hence, the B group CPS is poorly
immunogenic and, in principle, could induce autoantibodies
(Stein et al., 2006).
CPS conjugate vaccines designed to protect neonates from
intra- or postpartum bacterial infection through maternal immu-
nization are also in development. group B Streptococcus (S.
agalactiae, GBS) colonizes asymptomatically the ano-vaginal
tracts of up to 30% of women (Schuchat, 1998). Although GBS
is not pathogenic in healthy adults, newborn babies may be
colonized during birth, which can lead to severe septicemia,
pneumonia, or meningitis. There are nine known capsular sero-
types of GBS, and up to 10% of strains are nontypeable. It has
been demonstrated that risk of disease in the newborn correlates
with low levels of type-specific maternal IgG antibodies (Baker
and Kasper, 1976; Lin et al., 2001, 2004). It is believed that
high-titer maternal IgG can cross the placenta and confer pro-
tection to the newborn. Elderly people, particularly those with
underlying disease, are also at risk for serious infections by
GBS (Schuchat, 1999).
A common problem with CPS-based vaccines, in addition to
the serotype replacement by other known circulating serotypes
observed after the introduction of the 7-valent pneumococcal
vaccine, is that strains can shift in serotype and novel serotypes
Figure 1. Schematic Representation of the
Capsule Locus of Group B Streptococcus
Modified from Cieslewicz et al. (2005). Variable
glycosyltransferase genes that code for enzymes
which catalyze the specific sugar linkages are
flanked by genes coding for enzymes involved in
sialic acid synthesis and activation and genes
coding for proteins involved in polysaccharide
export.
can emerge. In GBS, for example, the
major circulating serotypes in the USA
and Europe are serotypes Ia, Ib, II, III,
and V, which are responsible for over
85% of disease. However, in Japan over
40% of isolates are of serotypes VI and
VIII (Lachenauer et al., 1999). Further-
more, serotype V was unknown in the
early 1980s and could therefore not ac-
count for more disease than the nontyp-
ables generally (Harrison et al., 1998; Zaleznik et al., 2000). To-
day, serotype V accounts for up to 20% of disease in neonates
and up to 50% of disease in the elderly.
Serotype replacement and serotype shift are two concepts
that are not necessarily related. The frequency with which differ-
ent circulating serotypes occur often varies over time. This well-
known observationmay be due to herd immunity andmay simply
reflect immune selection. The possible emergence of new
strains, with similar multilocus sequence typing but different
serotype, i.e., seroptype shift, is a different phenomenon that
may reflect the emergence of novel strains with increased
fitness.
Onemechanism of serotype shift is clear from the organization
of the genes which code for the synthesis and assembly of the
GBS capsule (Cieslewicz et al., 2005). Figure 1 shows schemat-
ically the organization of the capsule locus for GBS. The capsule
locus of all nine serotypes contains a number of conserved
genes likely to be involved in common functions such as sialic
acid synthesis and activation and polysaccharide transport.
These conserved genes flank glycosyltransferase genes that
vary both in number and sequence and are responsible for cat-
alyzing the specific sugar linkages in the polysaccharides of
each serotype, thus defining the capsule composition and struc-
ture. This appears to be a common theme in the structure of
capsule loci from many encapsulated bacteria (Yother, 1999).
It is likely that the variation in the glycosyltransferase region is
due to horizontal transfer of genes and recombination events.
It has been hypothesized that the much higher diversity found
in pneumococcal CPS (over 90 serotypes) may reflect a higher
frequency of DNA acquisition through natural competence in
pneumococcus (Cieslewicz et al., 2005).
The consequence of this mechanism of capsule diversity is
that capsule switching can occur and new serotypes can
emerge. It is clear that some hypervirulent lineages of N. menin-
gitidis, as defined by multilocus sequence typing, contain strains
with different serotypes (Brehony et al., 2007) indicating serotype
switching within the lineage. This conclusion is supported by
analysis of eight GBS genomes (Tettelin et al., 2002, 2005)
that clearly show that the genomes cluster to some extentCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 409
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polysaccharide conjugates can be very successful vaccines,
capsule diversity needs to be monitored continuously and new
serotypes added to the vaccine when necessary.
Protein Antigens
While CPS conjugate-based vaccines have been very successful
on the short to medium term, problems of serotype replacement
and serotype switching have encouraged an approach to vacci-
nation based on protein antigens. The paradigm, based on the
obvious efficacy of early toxoid-based vaccines, was initially to
try to understand the mechanisms of disease, identify the major
virulence factors, and use inactivated forms to induce protective
immunity. This approach has led to limited success. A very suc-
cessful acellular vaccine against Bordetella pertussis based on
the identification of major virulence factors, the pertussis toxin,
the filamentous hemagglutinin, and pertactin is currently avail-
able (Rappuoli, 1996). More recently, a vaccine against the
Gram-negative human gastric pathogen, Helicobacter pylori,
containing three important virulence factors which together con-
fer protection against intragastric H. pylori challenge in mouse
(Marchetti et al., 1995) and beagle dog (Rossi et al., 2004)models
is currently in clinical trials in humans (Ruggiero et al., 2003;more
on H. pylori later). The identification of these three H. pylori
virulence factors was a long and complex process. One factor,
a high-molecular weight, oligomeric protein exotoxin, VacA
(Reyrat et al., 1999), has been shown in mouse models to be
involved in the erosion of the gastric epithelium leading to ulcer-
ation (Telford et al., 1994). A second factor, CagA, encoded
within a pathogenicity island, is directly transferred to gastric
epithelial cells through a type IV secretion system and contrib-
utes to morphological transformation of the host cell (Bagnoli
et al., 2005; Covacci et al., 1999a). The third factor is a protein
that contributes to neutrophil activation and hence epithelial in-
flammation (Montecucco and de Bernard, 2003). Two of these
antigens in fact show some variation (Atherton, 2006), and only
a combination of all three are predicted to confer protection
against the most virulent strains.
On the other hand, attempts to develop a vaccine against
group A Streptococcus (S. pyogenes or GAS) based on the M
protein have encountered major hurdles due to the variability
of this protein between strains (Dale, 2008). The M protein
is the antigen recognized by sera used for M serotyping discov-
ered by Lancefield and colleagues over 50 years ago (Lancefield
and Perlmann, 1952). Early data, in mice and in studies in US
military recruits, demonstrated unequivocally that pharyngitis
caused by any single M serotype resulted in protection against
infection by any other strain of the same serotype but had no ef-
fect on infection by other serotypes (Lancefield, 1959). M protein
is a major virulence factor in GAS that is involved in evasion of
phagocytic attack and adhesion to host tissues (Bisno et al.,
2003). However, its intrinsic immunogenicity results in enormous
immune pressure to vary. In fact, there are over 130 known M
variants and crossprotection between M types is very limited
or nonexistent.
More recently, the basis of the second serotyping system of
Lancefield, the T-typing system, has, at least in part, been eluci-
dated (Mora et al., 2005). Lancefield described approximately 21
T serotypes, and it has been shown that at least four of these410 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.specificities are due to variants in the backbone protein of a pre-
viously unidentified pilus-like structure. Immunization with com-
ponents of these pili has been shown to confer protection
against strains carrying the same variant. From the known T se-
rotypes, it is likely that multiple T antigens would be required for
a vaccine capable of broad coverage. Nevertheless, there are an
estimated 21 T serotypes compared to over 130 M serotypes.
Pharyngitis may seem to be a problem of limited magnitude.
Unfortunately GAS is also responsible for several other more
serious invasive diseases such as septicemia and necrotizing
fasciitis (flesh-eating disease). Furthermore, nonsupurative se-
quelae of GAS infection include autoimmune rheumatic fever, re-
sulting in cardiac damage and glomerulonephritis, causing se-
vere kidney damage (Cunningham, 2008). The epidemiology of
GAS infection suggests a ray of hope in tackling this disease.
GAS pharyngitis peaks between the ages of 5 and 8 years, cor-
responding to the beginning of wider social contact among chil-
dren, and adults are rarely infected. It is unlikely that the protec-
tion in most adults can be explained by having been infected by
a sufficient number of M or T serotypes leading to the possibility
that there are more common but less immunodominant antigens
expressed by GAS that could be potential vaccine candidates.
Other attempts at vaccine development using the compo-
nents of adhesive pili of Gram-negative bacteria have failed to
result in successful vaccines. Both for pathogenic E. coli (Mor-
gan et al., 1978) and Neisseria gonorrhoeae (Johnson et al.,
1991), pilin subunits have been shown to induce protective im-
mune responses in animal models. Nevertheless, the fact that
these structures are essential for initial adhesion of the patho-
gens has resulted in strong immune system-driven variation in
the amino acid sequences of the pilin subunits. The net result
is that there is so much diversity in the pili that it has not been
possible to develop vaccines that could confer broad protection.
Hence, immunodominant antigens that are essential for viru-
lence in most pathogens are under tremendous pressure to
vary in order to evade the immune system of the host. This prob-
ably accounts for the majority of variation in amino acid se-
quence of potentially protective antigens. Novel approaches to
the design of vaccines will need to be based on the search for
antigens that are not exposed to immune pressure during infec-
tion and thus do not induce high levels of immunity in the course
of disease but which if used together with appropriate additional
antigens could lead to protective immunity.
Reverse Vaccinology: A Novel Genomic Approach
to Antigen Identification
The genome revolution of the mid-1990s has led to a quite differ-
ent approach to the identificationof vaccineantigens.Rather than
trying to identify virulence mechanisms, then identifying the fac-
tors involved, then cloning and expressing the genes coding for
these antigens, reverse vaccinology makes use of the availability
of the complete genome sequence of a pathogen (Rappuoli,
2001). Since the genome sequence gives the blueprint for every
potential protein antigen in the bacterium, a rigorous search
through the whole proteome must, by definition, identify protec-
tive antigens, if they exist. This approachwas first used to identify
protective antigens for serogroup B N. meningitidis (Pizza et al.,
2000)which, asmentioned above, has a capsular polysaccharide
shared with human tissues. The complete genome sequence of
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Individual strains of a species with an open pange-
nome share a conserved core genome. However,
up to 20% of each individual genome consists of
genes that are lacking in at least one genome.
The number of these ‘‘dispensable’’ genes may
be quite large, and hence the total gene pool avail-
able to the species would be correspondingly
large. Furthermore, dispensable genes may be
shared with other species leading to an overlap
in pangenomes. This is represented in the illustra-
tion as greater or less overlap between the pange-
nomes of related species.a strain of meningococcus B revealed about 2158 open reading
frames (Tettelin et al., 2000). Of these, 570 were predicted to
code for proteins that were either surface associated or secreted.
Each of these genes was cloned in E. coli expression vectors and
recombinant proteins from 350 of the clones were successfully
purified. These recombinant antigens were used to immunize
mice, and the resulting immune serumwas tested for its capacity
to promote bacterial killing in a complement dependent bacteri-
cidal assay. Serum bactericidal activity (SBA) in this assay is
known to correlate with protection in humans immunized with
CPS-conjugate vaccines against serogroups A, C, W, and Y.
From this analysis, 28 proteins were identified that could in-
duce SBA activity in mice. However, many of these antigens
were found to be highly variable as might be expected due to im-
mune pressure. In fact, no single antigen was capable of induc-
ing SBA activity against all strains in a panel of isolates designed
to reflect current population variability. Nevertheless, antigens in
combination were found that could confer protection against
a broad selection of strains (Giuliani et al., 2006).
Pangenome Reverse Vaccinology
The results obtained with meningococcus B led to a broader
approach to identify protein vaccine candidates for GBS: the ge-
nomes of eight different strains of GBS representing the major
disease causing serotypes were obtained and analyzed (Tettelin
et al., 2005). This analysis led to a rather surprising finding. Gene
variation between strains was found to be much higher than ex-
pected. Only about 80% of the approximately 2100 genes found
in any genome were shared by all genomes. About 20% of the
genes found in the genomes were lacking in at least one strain.
The total number of genes found in the eight strains was almost
50% greater than the size of the average genome. A mathemat-
ical analysis of these data indicated that further analysis of more
genomes would reveal even more genes. In fact, the extrapola-
tion of the data indicated that every time a new genome was
sequenced, one would expect to find between 15 and 30 new
genes not present in any of the previous genomes. How far
this model will hold up is yet unclear, but it is clear that the num-
ber of total genes in the global population of GBS may be very
high indeed (Medini et al., 2005). We have termed this concept
the pangenome (Tettelin et al., 2005). A schematic representa-
tion of the concept of the pangenome is shown in Figure 2.The probable mechanism of this genomic variability between
strains is horizontal transfer of DNA between strains and from
outside sources. But the data force the question of why the pan-
genome is so large. One possible answermay revolve around the
requirement for genome efficiency in bacteria. The pressure to
be energy efficient drives genomes toward the smallest possible
size and the least number of biochemical processes required for
the normal life cycle of the bacteria. Hence exclusively human
pathogens, e.g., the streptococci and H. pylori, have relatively
small genomes varying between 1.5 and 2.5 Mbp, whereas
Pseudomonas, which colonizes many niches and must survive
in a variety of environmental conditions has a genome of over
6Mbp. Perhaps, the very largepangenomeallows the global pop-
ulation of bacteria with small genomes to maintain sufficient var-
iability to confront novel conditions that may arise by, for exam-
ple, evolution of the host and/or increased immunity in the host.
From the eight GBS genomes, a total of 589 predicted surface
exposed or secreted proteins were identified, and 312 of these
were successfully expressed as soluble proteins and tested in
a mouse model of infection and disease. In order to reflect the
fact that most GBS neonatal disease occurs in the first week of
life and that high titers of maternal IgG can cross the placenta
and correlate with protection of the newborn, the model that
was used involved immunization of femalemice followed bymat-
ing and lethal challenge of the pups within the first 48 hr after
birth. As in the case of meningococcus B, no single antigen
was found that could confer protection against a broad range
of strains. Nevertheless, a combination of four antigens did con-
fer broad protection (Maione et al., 2005). Surprisingly, only one
of the genes among those encoding the four antigens was
shared among all eight strains sequenced, whereas the other
three were only present each in a subset of strains. These latter
dispensable proteins, surprisingly, were found to be compo-
nents of novel pilus-like structures (Lauer et al., 2005) with limited
variation (Rosini et al., 2006). Hence only one antigen belonged
to the core genome, and even this antigen was not universally
expressed in all strains. There is a certain sense in this pattern.
Onemight imagine that the core genome of this pathogen, which
is capable of chronic ano-genital carriage, must not, by neces-
sity, be particularly immunogenic or confer protection, in con-
trast to more virulent acute pathogens that rely on new cohorts
of nonimmune hosts for their maintenance.Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 411
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pangenomes. Examples include E. coli (Marrs et al., 2005), GAS,
and pneumococcus (Medini et al., 2005). However, not all path-
ogens have open-ended genomes. After the analysis of only four
genomes for Bacillus anthracis, for example, no new genes were
found (Tettelin et al., 2005). The probable reason for this is thatB.
anthracis is believed to be a relatively recent subclone of the very
much more variable Bacillus cereus.
The Strange Case of Helicobacter pylori
Asmentioned above, a vaccine againstH. pylori containing three
components is currently in clinical evaluation in humans. While
this vaccine is predicted to be widely protective, two of the
antigens identified as virulence factors, the vacuolating cytotoxin
VacA and CagA, an effector molecule transferred to host cells,
are in fact variable (Atherton, 2006). There are two major alleles
of VacA and expression of functional VacA varies due to variation
in the signal peptide and N terminus of the molecule (Atherton
et al., 1995). CagA, on the other hand, is a component of a path-
ogenicity island coding for a type IV secretion system which is
present in only a subset of strains (Censini et al., 1996). Never-
theless, strains containing the pathogenicity island and which
express VacA are associated with more serious H. pylori disease
including peptic ulcer and gastric cancer (Atherton, 1997).
GenomeanalysisofH.pylorihas, however, revealedahigh level
of diversity. Individual isolates of H. pylori differ in gene content,
gene similarity, and even genome structure (Tomb et al., 1997;
Alm et al., 1999). Themajormechanismdriving variability inH. py-
lori is believed to be horizontal transfer of DNA between strains
and between H. pylori and other pathogens due to its capacity
to actively acquire foreign DNA (Karnholz et al., 2006). Based on
multilocus sequence typing (Karnholz et al., 2006) andmicroarray
analysis (Salama et al., 2000), the core genome of H. pylori has
been estimated as between 1100 to 1300 of the approximately
1600 genes in the genome of any single strain. Remarkably, indi-
vidual isolates from the same patient (Israel et al., 2001) often dif-
fer in gene content, and isolates fromdifferent hosts are generally
distinguishable by genome analysis (Salama et al., 2000).
To understand this diversity, one must consider the niche and
lifestyle ofH. pylori. This bacterium is an exclusively human path-
ogen with an exclusive niche in the stomach. Hence, H. pylori
requires a very small genome to meet its needs. Furthermore,
H. pylori colonizes between 30% and 90% of the human popu-
lation. Colonization usually occurs in childhood, mainly from
within the family or close contacts and persists for the life of
the individual. Infection causes peptic ulcer disease in about
20% of those infected and is strongly associated with gastric
cancer in a smaller number of cases. H. pylori has been a con-
stant companion of man for at least thousands of years (Covacci
et al., 1999b). Early studies of H. pylori indicated that variation in
the genes coding for virulence factors VacA and CagA were
associated with specific geographic variations. From this obser-
vation, it was suggested that H. pylori had colonized humans at
a very early stage of our evolution and that it had evolved to-
gether with humans as they spread around the globe. More
recently, this concept has been powerfully substantiated by
seminal studies by Suerbaum, Achtman, and colleagues (re-
viewed in Suerbaum and Achtman, 2004) who have shown a di-
rect association between the H. pylori population structure and412 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.that of man. They found that the worldwide H. pylori population
could be subdivided in seven major groups originating in Africa,
Central Asia, and East Asia (Falush et al., 2003) and showed that
these subtypes associated with human subpopulations or even
ethnic groups (Wirth et al., 2004). They conclude that the ances-
tralH. pylori arose in East Africa, where it is believedmodernman
arose and began his migrations, and thatH. pylori has coevolved
with its human host.
SinceH. pylori colonizes for the life of the host, despite a vigor-
ous humoral immune response, it is unlikely that the genomic
and proteomic variation is due to immune pressure. An explana-
tion of coevolution with its host is muchmore plausible. It is likely
that H. pylori has adapted to human diversity, perhaps in major
histocompatibility complex, blood group antigens (which are
receptors forH. pylori adhesins [Aspholm et al., 2006]), and other
host-specific diversity in its gastric niche. Hence, while immune
pressure is certainly a driving force in bacterial variation, other
mechanismsmay play important roles in this phenomenon. Inde-
pendently of the mechanisms driving variation, the result for
vaccine development is still the same: novel vaccines most
probably will need multiple antigens in order to achieve broad
coverage.
Antigen Variability Due to Variations in Gene Expression
Bacteria are under constant evolutionary pressure for efficiency.
Energy requirements for DNA replication, transcription, protein
synthesis, and macromolecule synthesis account for the major
part of energy turnover in the cell. Hence evolutionary pressure
selects for small efficient genomes carrying only the genes re-
quired to code for the minimally required metabolic pathways
necessary for life in the particular niche. The cost of this genome
reduction is a reduced flexibility to variations in the environment
such as nutrient sources, niche variation, and immune re-
sponses. This latter is particularly important for pathogenic
species restricted to a particular host. As discussed above,
one strategy to deal with environmental variation is to have
a large and varied pangenome. In this way, individual bacteria
of species such as streptococci may have a relatively small ge-
nome, but the total number of dispensable genes in the popula-
tion permits sufficient flexibility for the species to adapt to envi-
ronmental challenge. On the other hand, the long association of
H. pylori with its human host has permitted a continual coevolu-
tion as the host environment has altered.
For more rapid responses to environmental changes, bacteria
have evolved systems for regulated gene expression. This
means that the genome must carry the necessary genes, but
considerable energy can be saved by only expressing those
genes required for the particular stage of its life cycle. For very
rapid responses, gene regulation relies on sensing the environ-
ment and regulating the expression of appropriate genes at the
transcriptional level through transcriptional regulators. These
are frequently two-component systems consisting of a sensor
histidine kinase that when activated phosphorylates and thus ac-
tivates a transcriptional regulator (Mascher et al., 2006). These
types of responses occur at the level of individual bacteria.
A second mechanism of gene regulation which acts at the
bacterial population level is based on genetic switching on or
off of genes by genomic changes. Genes regulated in this fash-
ion are usually referred to as contingency genes. There are two
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Slipped-Strand Mispairing during DNA
Replication
In this example of a four base repeated sequence,
the polymerase skips one repeat in the template
strand (black), and the nascent strand lacks one
repeat. Excision repair can then either repair the
nascent strand, such that the number of repeats
is maintained, or the template strand, resulting in
deletion of a repeat. In bacteria that use the Dam
system, methylation of the template strand directs repair predominantly to the nascent strand. In the absence of Dam, the template and nascent strands can
be repaired with equal likelihood, thus increasing the frequency of repeat number variation.major mechanisms of controlling the expression of contingency
genes. The first relies on homologous recombination between
identical sequences flanking a cassette of gene sequences
(Zieg et al., 1977). Recombination results in reversing the direc-
tion of the entire cassette such that in one orientation the gene
can be transcribed whereas in the other the gene is off (Silver-
man et al., 1979). This mechanism is dependent on a functional
RecA system.
Another mechanism of genetic gene regulation is through
short sequence repeats of up to four base pairs (thoroughly re-
viewed [Moxon et al., 2006]). These regions are highly suscepti-
ble tomutation through slipped-strandmispairing during replica-
tion that results in either shortening or lengthening the repeat
region (Figure 3). For example, extending a short homopolymeric
run of a single nucleotide in a coding sequence by one or two
nucleotides would result in a shift of reading frame eliminating
correct translation of the mRNA. Furthermore, variation in the
length of repeated sequences upstream of a coding sequence
between the promoter and the transcriptional start site can
have profound effects on the efficiency of transcriptional initia-
tion, thus effectively modulating the level of expression of the
gene (Dawid et al., 1999; van Ham et al., 1993). Switching genes
on or off by this mechanism is independent of RecA but may be
to some extent depend on the integrity of DNA repair systems
(Bayliss et al., 2002; Bucci et al., 1999; Martin et al., 2004;
Richardson and Stojiljkovic, 2001).
This is not a rare mechanism for the control of gene expres-
sion. In the genome of N. meningitides, there are about 80
different repeated segments predicted to be involved in phase
variation (Snyder et al., 2001). Several of these control the on-
off switching of expression of surface molecules including cap-
sule synthesis (Hammerschmidt et al., 1996). In serogroup Bme-
ningococci, phase variation resulting in loss of capsule synthesis
favors cell invasion and may be necessary for invasive disease
(Stephens et al., 1993). On the other hand, capsule is an impor-
tant virulence factor helping to protect the bacteria from both in-
nate and adaptive immune responses in the blood phase of in-
fection (Taylor and Roberts, 2005; Vogel et al., 1996). Phase
variation of capsule synthesis in serogroup B meningococci in-
volves a homopolymeric run of dC in the polysialyltransferase
gene (siaD) (Hammerschmidt et al., 1996). Loss or gain of a single
residue results in either an intact open reading frame or a frame
shift leading to a truncated protein. Since phase variation at
this locus is RecA independent, it is assumed that the variation
is due to slipped-strand mispairing (Murphy et al., 1989).
More recently, it hasbeen reported that capsulephasevariation
in serogroup Bmeningococcus is at least 100-foldmore frequent
in strains lacking a DNA adeninemethyltransferase (Dam) systemthan in strains with functional Dam system (Bucci et al., 1999).
Since the Dam methylase functions to mark the template strand
such that repair of polymerase errors is focused to the newly syn-
thesized strand, in the absence of this activity, the repair can oc-
cur equally frequently on both strands thus perpetuating the er-
rors. Interestingly, in this study it was observed that all of 24
invasive strains tested lacked the Dam activity, whereas only
50% of 24 carrier strains lacked this enzyme, suggesting that, at
least in part, increased frequency of phase variation may contrib-
ute to virulence through favoring rapid changes from cell invasive
capsule negative forms to immune system resistant forms in the
blood phase of infection (Bucci et al., 1999). This latter hypothesis
is very attractive.However,more recent data havequestioned the
importance of theDamsystem in frequency of capsule phase var-
iation (Martin et al., 2004; Richardson and Stojiljkovic, 2001).
Phase variation may not necessarily exclude a protein from
being a candidate to confer immune protection. By targeting
antigens that are necessary for specific stages during the infec-
tious cycle, for example, factors necessary for survival in the
blood of pathogens that cause septicemia, vaccines against
even phase variable genes could be successful.
Conclusion
Vaccination is one of the great medical success stories. We are,
in a way, fortunate that many of the life-threatening diseases of
childhood relied on new nonimmune cohorts of young children
for their continued existence and thus did not evolve much var-
iation in virulence factors. Furthermore, zoonotic diseases such
as rabies only infrequently infected humans and thus were not
under selective pressure. Through the study of natural immunity
to these diseases, the concept of immunology was born, which
led to vaccines that have essentially eradicated the diseases
(at least in the industrialized world). But, the easy ones have all
been done. The low-hanging fruits have been picked. Antigenic
variation is the bane of vaccinologists. New strategies usingmul-
tivalent vaccines are beginning to be successful against these
more intractable pathogens, but the war on infectious disease
has only just begun, and the challenge of viral antigen variation
has still to be addressed.
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